Skip to main content
. 2020 Jan 21;4(2):230–237. doi: 10.1002/rth2.12292

Table 2.

Patient characteristics and outcomes according to predicted risk tertiles

  Lowest tertile (N = 2103) Middle tertile (N = 2135) Highest tertile (N = 2221) P value
Treatment with betrixaban, n (%) 1031 (49.0) 1036 (48.5) 1140 (51.2) .15
Treatment with enoxaparin, n (%) 1073 (51.0) 1099 (51.5) 1081 (48.8) .15
Primary outcome event, n (%) 58 (2.8) 109 (5.1) 240 (10.8) <.001
Age, y, mean (SD) 73.83 (7.24) 77.23 (7.40) 77.78 (9.40) <.001
Male (%) 988 (47.0) 967 (45.3) 969 (43.6) .09
Weight, kg, mean (SD) 85.17 (20.56) 78.53 (17.48) 78.11 (18.68) <.001
BMI, kg/m2, median (IQR) 29.60 (25.90‐35.50) 28.10 (24.60‐32.10) 27.50 (24.20‐32.00) <.001
Duration of hospitalization, days, median (IQR) 9.00 (7.00‐13.00) 10.00 (7.75‐14.00) 11.00 (8.00‐15.00) <.001
Creatinine clearance, mL/min, mean (SD) 75.84 (33.15) 69.93 (31.32) 68.08 (33.71) <.001
Race (%)
White 1996 (95.7) 1992 (95.1) 2075 (95.7) .73
Black 37 (1.8) 35 (1.7) 44 (2.0)  
Asian 4 (0.2) 7 (0.3) 2 (0.1)  
American Indian 2 (0.1) 3 (0.1) 2 (0.1)  
Pacific Islander 0 (0.0) 1 (0.0) 0 (0.0)  
Multiple 14 (0.7) 18 (0.9) 12 (0.6)  
Other 32 (1.5) 39 (1.9) 33 (1.5)  
Use of strong P‐gp inhibitor, n (%) 383 (18.2) 352 (16.5) 426 (19.2) .07
D‐dimer, median (IQR) 0.69 (0.39‐1.11) 1.24 (0.76‐1.83) 2.70 (1.52‐4.37) <.001
History of cancer, n (%) 217 (10.3) 275 (12.9) 267 (12.0) .031
History of thrombosis, n (%) 2 (0.1) 13 (0.6) 497 (22.4) <.001
Chronic heart failure, n (%) 500 (23.8) 467 (21.9) 503 (22.6) .33
Acute infectious disease, n (%) 313 (14.9) 356 (16.7) 340 (15.3) .24
Severe varicosities, n (%) 475 (22.6) 312 (14.6) 414 (18.6) <.001
Hormone replacement, n (%) 4 (0.2) 14 (0.7) 41 (1.8) <.001
Inherited or acquired thrombophilia, n (%) 2 (0.1) 2 (0.1) 3 (0.1) .89

BMI, body mass index; IQR, interquartile; P‐gp, P‐glycoprotein; SD, standard deviation.